Environmental and Occupational Exposure: Chronic inhalation of inorganic and organic particulates, such as silica, asbestos, ...

Pulmonary fibrosis (PF) is a progressive interstitial lung disease (ILD) characterized by excessive fibrotic tissue ...

The outcomes of patients with idiopathic pulmonary fibrosis (IPF) remain unknown. Alongside the global adoption of antifibrotic therapies, there is currently relentless research for biomarkers and ...

In idiopathic pulmonary fibrosis, higher risk of mortality and lung transplant is linked to small decreases in FVC% predicted and DLCO% predicted.

Late-breaking oral presentation to highlight further evidence supporting potential for deupirfenidone to serve as a new standard of care for the treatment of idiopathic pulmonary fibrosis (IPF) ...

Rein previously announced positive topline results from Cohort 2 (5 mg BID) of the Phase 1b clinical trial of LTI-03 in IPF, in which a positive trend was observed in seven out of eight biomarkers ...

PureTech to Present Results from Phase 2b ELEVATE IPF Trial of Deupirfenidone (LYT-100) at the American Thoracic Society International Conference  Late-breaking oral presentation to highlight further ...

It has an average survival time of only three to five ... The future of another experimental oral pulmonary fibrosis treatment – Pliant Therapeutics' αvβ6 and αvβ1 integrin inhibitor ...

Barrow in Furness will soon say goodbye to one of its best 'top welders', Geoff Mattimore, who died of a rare lung condition Idiopathic ...

Researchers have developed a novel rat model that closely replicates the pathological features and physiological changes ...